Argenx
ARGX
#530
Rank
$35.69 B
Marketcap
$555.11
Share price
-5.92%
Change (1 day)
43.55%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Annual Reports (20-F)

Latest form 20-F annual reports for Argenx CIK: 0001697862
The 20-F is a 10-K equivalent for non-US companies, as a foreight company Argenx only files 20-F reports

Thumbnail Argenx
 20-F Annual Report 2024

20-F Annual Report 2024

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report 2023

20-F Annual Report 2023

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report 2022

20-F Annual Report 2022

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report 2021

20-F Annual Report 2021

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report 2020

20-F Annual Report 2020

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report 2019

20-F Annual Report 2019

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report 2018

20-F Annual Report 2018

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report 2017

20-F Annual Report 2017

Language: English

View Annual Report (20-F)